Adagio Medical Holdings, Inc. (ADGM) Stock Price & Analysis
Adagio Medical Holdings, Inc. (ADGM) rose 0.62% to USD 0.75 as of June 10, 2026 at 10:46 UTC, according to Nexqual real-time market data.
ADGM last closed at USD 0.74; the session ranged USD 0.73–0.79 on volume of 64,541 shares. Market capitalization is $16.62M, with a 52-week range of USD 0.7–2.58 (NCM). Source: Nexqual, June 10, 2026 at 10:46 UTC.
Key Statistics (as of June 10, 2026 at 10:46 UTC)
| Price | USD 0.75 |
|---|---|
| Change | ▲ 0.62% (up) |
| Previous Close | USD 0.74 |
| Open | USD 0.76 |
| Day Range | USD 0.73 – 0.79 |
| 52-Week Range | USD 0.7 – 2.58 |
| Volume | 64,541 shares |
| Market Cap | $16.62M |
| Exchange | NCM |
Technical Analysis (ADGM)
Nexqual's technical model rates ADGM "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 10:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.92 (oversold) |
| vs SMA50 | Below (USD 1.07) |
| MACD | -0.09 (negative) |
Analyst Ratings (ADGM)
Wall Street analysts rate ADGM "Strong Buy" based on 3 analysts, with a mean price target of USD 3.33 (range USD 3–4), per Nexqual as of June 10, 2026 at 10:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.33 |
| High Target | USD 4 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (ADGM)
| EPS Estimate | USD -0.27 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.29 ▼ miss |
| 2025-12-31 | USD -0.16 vs est -0.31 ▲ beat |
Source: Nexqual, June 10, 2026 at 10:46 UTC.
Financials & Fundamentals (ADGM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -268.88% |
| Debt / Equity | 420.77 |
| Current Ratio | 1.85 |
| Total Cash | $12.91M |
| Total Debt | $24.09M |
| Free Cash Flow | $-7.78M |
Source: Nexqual, June 10, 2026 at 10:46 UTC.
Financial Health Score (ADGM)
Nexqual rates Adagio Medical Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Critical — $13M cash vs $24M debt |
| Cash Flow | Weak — Operating cash flow -$16M |
| Efficiency | Critical — ROE -269%, ROA -30.5% |
Ownership (ADGM)
| Insider Ownership | +3.41% |
|---|---|
| Institutional Ownership | +70.50% |
| Shares Outstanding | 22.21M |
| Float | 4.81M |
| Short % of Float | +0.53% |
Source: Nexqual, June 10, 2026 at 10:46 UTC.
Leadership (ADGM)
Adagio Medical Holdings, Inc. is led by Todd Usen (age 58), CEO & Director, per Nexqual as of June 10, 2026 at 10:46 UTC.
| CEO & Director | Todd Usen (age 58) |
|---|---|
| CFO & Chief Business Officer | Deborah Kaster (age 54) |
| Senior Vice President of Manufacturing & Operations | Antwan Gipson |
| Vice President of Global Marketing & Product Management | Ilya Grigorov |
| Senior Vice President of Global Sales | Marie-Claude Jacques (age 40) |
Major Backers & Investors (ADGM)
Notable institutional backers of Adagio Medical Holdings, Inc. include Perceptive Advisors Llc, Sio Capital Management, LLC, Adage Capital Partners GP L.L.C., according to Nexqual as of June 10, 2026 at 10:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Perceptive Advisors Llc | 44.47% |
| Sio Capital Management, LLC | 5.8% |
| Adage Capital Partners GP L.L.C. | 5.67% |
| Adar1 Capital Management, LLC | 5.43% |
| Alyeska Investment Group, L.p. | 5.22% |
| SilverArc Capital Management, LLC | 1.13% |
| Shaolin Capital Management LLC | 0.77% |
| Fidelity | 0.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.56% |
| Vanguard Group | 0.42% |
Source: Nexqual, June 10, 2026 at 10:46 UTC.
From Adagio Medical Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Adagio Medical Holdings, Inc., a medical technology company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
- It offers treatment for cardiac arrhythmias, including atrial fibrillation, and ventricular tachycardia.
- The company's product portfolio includes iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system; vCLAS ventricular ULTC catheter; and Cryopulse pulsed field cryoablation catheters.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMIX | Autonomix Medical, Inc. | USD 0.4 | ▼ 1.29% |
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
| IBG | Innovation Beverage Group Limit | USD 1.2 | ▲ 3.45% |
| KAPA | Kairos Pharma, Ltd. | USD 0.43 | ▼ 2.05% |
| AMOD | Alpha Modus Holdings, Inc. | USD 0.17 | ▼ 18.68% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:46 UTC. This page is informational and not investment advice.